Products
Amulirafusp Biosimilar Antibody Fusion Protein (CD20) for Research
Cat No.: GMP-Bios-INN-1079
Anti-MS4A1/CD20 therapeutic antibody (Pre-made Amulirafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Amulirafusp (development code IMM-0306) is an antibody fusion protein incorporating a signal regulatory protein alpha (SIRPalpha) fragment that binds CD47. It is developed by ImmuneOnco Biopharmaceuticals for cancer. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1079-1mg | 1mg | 3090 |
| GMP-Bios-INN-1079-10mg | 10mg | |
| GMP-Bios-INN-1079-100mg | 100mg | |
| GMP-Bios-INN-1079-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Amulirafusp biosimilar, Whole mAb Fusion, Anti-MS4A1/CD20 Antibody: Anti-CD20/MS4A1/B-lymphocyte antigen CD20/B-lymphocyte surface antigen B1 therapeutic antibody |
| INN Name | Amulirafusp |
| Target | MS4A1/CD20 |
| Format | Whole mAb Fusion |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 4kaq:HL/2osl:AB:HL/4kaq:HL/6y90:HL:CD/6vja:HL:IM/8vgn:AB:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | ImmuneOnco Biopharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Oncology |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
